Resource Summary Report

Generated by RRID on Aug 7, 2026

HER3/ErbB3 (1B2E) Rabbit mAb

RRID:AB_10691324
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4754, RRID:AB_10691324

Antibody Information

URL: http://antibodyregistry.org/AB_10691324

Proper Citation: Cell Signaling Technology Cat# 4754, RRID:AB_10691324

Target Antigen: HER3/ErbB3 (1B2E) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP. Consolidation on 11/2018: AB_10691324, AB_2099727.

Antibody Name: HER3/ErbB3 (1B2E) Rabbit mAb

Description: This monoclonal targets HER3/ErbB3 (1B2E) Rabbit mAb

Target Organism: rat, h, m, mouse, r, human

Clone ID: Clone 1B2E

Antibody ID: AB_10691324

Vendor: Cell Signaling Technology

Catalog Number: 4754

Record Creation Time: 20250820T040305+0000

Record Last Update: 20250820T175403+0000

Ratings and Alerts

No rating or validation information has been found for HER3/ErbB3 (1B2E) Rabbit mAb.

No alerts have been found for HER3/ErbB3 (1B2E) Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene, 45(31), 3244.

Ma K, et al. (2026) ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging. Cell, 189(11), 3413.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. Cell chemical biology, 32(6), 839.

Gadal S, et al. (2025) Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. Cancer research, 85(9), 1611.

Wang H, et al. (2023) Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer cell, 41(7), 1345.

McLean JW, et al. (2022) Disruption of Endosomal Sorting in Schwann Cells Leads to Defective Myelination and Endosomal Abnormalities Observed in Charcot-Marie-Tooth Disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 42(25), 5085.

Mukherjee R, et al. (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Molecular cell, 81(4), 708.

De Bacco F, et al. (2021) ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. Cell reports, 36(4), 109455.

Koga T, et al. (2021) Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. Translational lung cancer research, 10(8), 3659.

Koivu MKA, et al. (2021) Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases. Molecular cancer therapeutics, 20(3), 564.

Zhang Z, et al. (2020) Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer cell, 38(2), 279.

Jard?? T, et al. (2020) Mesenchymal Niche-Derived Neuregulin-1 Drives Intestinal Stem Cell Proliferation and Regeneration of Damaged Epithelium. Cell stem cell, 27(4), 646.

Geuijen CAW, et al. (2018) Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade. Cancer cell, 33(5), 922.